septin 4Genealiases: ARTS · BRADEION · C17orf47 · CE5B3 · H5 · MART
Q-omics provides the consensus-scored SEPTIN4 profile across patient tissues and cancer cell-line models. SEPTIN4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SEPTIN4 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, SEPTIN4 protein abundance shows 41,723 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, and LUAD as cancer lineages where SEPTIN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEPTIN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEPTIN4 survival associations across molecular data types. SEPTIN4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEPTIN4 RNA expression–survival associations across cancer types. High SEPTIN4 expression shows unfavorable associations in KIRP, COAD, ACC, STAD and BLCA, but favorable associations in LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SEPTIN4 RNA expression.
This table summarizes SEPTIN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SEPTIN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEPTIN4 shows lower tumor expression in LUAD, KICH, KIRP, LUSC and BRCA and higher tumor expression in KIRC. The LUAD box plot shows higher SEPTIN4 RNA expression in normal versus tumor tissue (log2 FC = −1.495, t-test p < 0.001).
This table shows molecular features associated with SEPTIN4 in patient tissues and cancer cell lines. In patient samples, SEPTIN4 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SEPTIN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
